Agenus Inc

Quantli Newsdesk

· a month ago

Agenus secured up to $340 million in private placement financing to fund its ROBBIN Phase 3 trial evaluating botensilimab plus balstilimab in high-risk stage 2 and 3 MSS colon cancer. The company discontinued financial support for its BATTMAN Phase 3 study in metastatic colorectal cancer to concentrate resources on the neoadjuvant setting, which management views as the highest impact opportunity.